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Abstract
Background and Objective Bodyweight-based dosing of tacrolimus is considered standard care. Currently, at first steady 
state, a third of pediatric kidney transplant recipients has a tacrolimus pre-dose concentration within the target range. We 
investigated whether adaptation of the starting dose according to a validated dosing algorithm could increase this proportion.
Methods This was a multi-center, single-arm, prospective trial with a planned interim analysis after 16 patients, in which the 
tacrolimus starting dose was based on bodyweight, cytochrome P450 3A5 genotype, and donor status (living vs. deceased 
donor).
Results At the interim analysis, 31% of children had a tacrolimus pre-dose concentration within the target range. As the 
original dosing algorithm was poorly predictive of tacrolimus exposure, the clinical trial was terminated prematurely. Next, 
the original model was improved by including the data of the children included in this trial, thereby doubling the number 
of children in the model building cohort. Data were best described with a two-compartment model with inter-individual 
variability, allometric scaling, and inter-occasion variability on clearance. Cytochrome P450 3A5 genotype, hematocrit, and 
creatinine influenced the tacrolimus clearance. A new starting dose model was developed in which the cytochrome P450 
3A5 genotype was incorporated. Both models were successfully internally and externally validated.
Conclusions The weight-normalized starting dose of tacrolimus should be higher in patients with a lower bodyweight and 
in those who are cytochrome P450 3A5 expressers.
Key Points 
A validated dosing algorithm could poorly predict the 
individual starting dose of tacrolimus following renal 
transplantation in cytochrome P450 3A5 expressers 
receiving a kidney from a deceased donor.
The dosing algorithm was improved and the weight-
normalized starting dose of tacrolimus should be higher 
in patients with lower bodyweight and in those who are 
cytochrome P450 3A5 expressers.
This study demonstrates that even though a model is 
validated on paper, it is not necessarily effective in clini-
cal practice. Dosing algorithms should first be tested in 
prospective studies.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-019-00831 -8) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Tacrolimus is the most commonly used immunosuppres-
sant to prevent acute rejection following renal transplan-
tation [1–4]. Because of its huge medical impact, tacroli-
mus was chosen by scientists as one of the five molecules 
to take to a remote island [5]. Nonetheless, prolonged 
use of tacrolimus leads to substantial toxicity, includ-
ing increased rates of infection, post-transplant diabetes 
mellitus, nephrotoxicity, neurotoxicity, hypertension, and 
gastrointestinal disturbances [6–9]. These adverse events 
contribute to the limited long-term patient and kidney allo-
graft survival and patient non-adherence [10, 11]. Adverse 
events seem to be related to higher tacrolimus concentra-
tions, whereas rejection rates seem to be related to lower 
concentrations [12, 13]. It is thus important to reach the 
tacrolimus target concentration as soon as possible to limit 
the risk of rejection and reduce toxicity [12, 14].
Tacrolimus is a critical dose drug with a narrow thera-
peutic index and large intra- and interpatient variability, 
for which therapeutic drug monitoring (TDM) is rou-
tinely performed [13]. Many factors, including age [15, 
16], bodyweight [17–19], cytochrome P450 (CYP) 3A 
genotype [17, 19], drug–drug interactions [20, 21], eth-
nicity [22, 23], and hematocrit [17, 19, 24, 25] influence 
the pharmacokinetics of tacrolimus. Contrary to adults, 
most published pediatric population pharmacokinetic (PK) 
models have included either bodyweight or age as a sig-
nificant covariate influencing clearance (CL) [21, 26]. To 
reach the target range, children aged younger than 5 years 
require higher weight-normalized tacrolimus doses than 
older children [15]. Currently, in clinical practice and at 
first steady state, only 30% of patients are within the target 
range. Two thirds of children have a concentration outside 
the target range, 63.5% having subtherapeutic concentra-
tions, and 6.5% have supratherapeutic concentrations [17]. 
In daily practice, the starting dose is often based solely on 
bodyweight, subsequent doses are adjusted using TDM, 
which limits the time a patient is exposed to concentra-
tions outside the target range, but it can still take up to 
3 weeks before target concentrations are reached [17].
The use of a population PK model may help in predict-
ing an individual’s tacrolimus exposure and can be applied 
before the start of therapy. Recently, our group developed a 
dosing algorithm to predict the right tacrolimus starting dose 
in pediatric renal transplant recipients [17]. In this model, 
the starting dose is based on bodyweight, CYP3A5 geno-
type, and donor status (living vs. deceased). The model was 
extensively validated, both internally (bootstrap analysis, 
visual predictive check [VPC] and normalized prediction 
distribution errors) and externally (VPC) in an independent 
cohort consisting of 23 pediatric renal transplant recipients.
Here, we report the results of a prospective clinical trial in 
pediatric renal transplant recipients in which the tacrolimus 
starting dose was based on this dosing algorithm [17]. The 
aim of this trial was to determine if basing the starting dose 
of tacrolimus on the validated dosing algorithm leads to a 
higher proportion of patients reaching the tacrolimus target 
pre-dose concentration (C0) range (10–15 ng/mL) at day 3 
after transplantation. The number of children we planned to 
include was 28 and an interim analysis was planned after the 
inclusion of 16 children. The interim analysis demonstrated 
that the algorithm did not adequately predict the tacrolimus 
exposure and therefore the trial was stopped. Subsequently, 
a new and improved dosing algorithm was developed in a 
cohort in which the total number of included children was 
doubled compared to the original cohort.
2  Methods
2.1  Clinical Trial
This was an investigator-initiated, prospective, open-
label, multi-center clinical trial. Pediatric patients (aged 
2–18 years) who were scheduled to receive a single-organ, 
blood group AB0-compatible kidney at the Erasmus MC-
Sophia Children’s Hospital in Rotterdam or the Radbou-
dumc-Amalia Children’s Hospital in Nijmegen were eligible 
for participation. Patients who received immunosuppressive 
drug treatment in the 28 days prior to transplantation (with 
the exception of glucocorticoids) and/or used drugs known 
to interact with tacrolimus (Table S1 of the Electronic Sup-
plementary Material [ESM]) were not included in the study.
All procedures performed in studies involving human 
participants were in accordance with the ethical standards 
of the institutional research committee (Erasmus MC, Medi-
cal Ethical Review Board number 2017-393) and with the 
1964 Helsinki Declaration and its later amendments or com-
parable ethical standards. The study was registered in the 
Dutch national trial registry (https ://www.trial regis ter.nl/
trial /6694). Written informed consent was obtained from 
all patients and/or their parents depending on the age of the 
patient before inclusion in the study. The PK study was also 
approved by the institutional review board of the Erasmus 
MC (Medical Ethical Review Board number 2017-092).
2.1.1  Intervention
Patients were prescribed a tacrolimus starting dose based 
on a published dosing algorithm [17]. This original dosing 
algorithm is shown in Eq. (1):
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The dose was adjusted based on bodyweight, CYP3A5 
status, and donor type. The dosing guideline ranged from 
0.27 to 1.33 mg/kg as shown in Table S2 of the ESM. Both 
twice-daily formulations  Prograft® capsules and  Modigraf® 
granules for suspension (Astellas Pharma, Leiden, the 
Netherlands) were used. All doses were divided into two 
equal daily doses administered every 12 h. All patients 
were treated according to the TWIST protocol with basi-
liximab, tacrolimus, mycophenolic acid, and a 5-day course 
of glucocorticoids [14]. Patients were followed for 10 days 
post-transplantation.
2.1.2  Endpoints
The primary endpoint was the proportion of patients within 
the tacrolimus C0 target range (10–15 ng/mL) after five 
unaltered tacrolimus doses on day 3 (first steady state) after 
transplantation. Hereafter, the physician could change the 
tacrolimus dose based on the tacrolimus C0 or the clinical 
status of the patient. Subsequently, C0 were drawn frequently 
according to local hospital protocol. Clinicians were encour-
aged to use the following formula to calculate the new dose:
Secondary endpoints included the proportion of patients 
within the target range on day 7 and 10 following transplan-
tation, and the proportion of patients with markedly sub-
therapeutic (< 5.0 ng/mL) or supra-therapeutic (> 20 ng/mL) 
tacrolimus C0 on day 3. Clinical endpoints included the inci-
dence of biopsy-proven acute rejection and serious adverse 
events during follow-up (10 days) and the 30 days after the 
follow-up period. Delayed graft function was defined as the 
need for dialysis in the first week after transplantation.
2.1.3  Laboratory Analysis
Tacrolimus concentrations were determined using a vali-
dated liquid chromatography–tandem mass spectrom-
etry method as described previously [17]. Genotyping for 
CYP3A4 and CYP3A5 was performed as described previ-
ously [17].
Dose (mg/day)
= 209 ng h/mL ∗ 54.9 ∗
(
weight
70
)0.75
∗ (1.8, ifCYP3A5 ∗ 1∕ ∗ 3 orCYP3A5 ∗ 1∕ ∗ 1)
∗ (0.74, if living donor)∕1000.
New tacrolimus dose
=
(
desired tacrolimusC
0
current tacrolimusC
0
)
∗ current tacrolimus dose.
2.1.4  Statistical Analysis
With standard tacrolimus dosing, the percentage of patients 
with a tacrolimus C0 within the therapeutic target range on 
day 3 after transplantation is 30% in our population [17]. 
With model-based dosing, this was expected to increase to 
at least 55%. For the sample size of the study, a minimax 
Simon two-stage design was used [27]. With α = 0.1 and 
β = 0.10, the required number of patients was 25 with an 
interim analysis involving the first 16 included patients. If 
after the inclusion of 16 patients, four or fewer patients (or 
25%) were on target, inclusion of further patients would be 
terminated. The conclusion of the trial would then be that 
model-based dosing does not result in a sufficiently high pro-
portion of patients with a C0 on target. If at least five patients 
(or 31%) had a tacrolimus C0 within the target range, inclu-
sion would be extended. The conclusion of the trial would 
then be that model-based dosing is effective and results in a 
sufficiently high proportion of patients with an adequate C0 
to warrant further research in this population. To account for 
a 10% dropout, it was estimated that a total of 28 patients 
had to be included.
For the analysis, an intention-to-treat approach was fol-
lowed, which included all patients who received at least 
one dose of the assigned drug. All secondary endpoints are 
described for the study population, and also for the historic 
controls. These historic controls are the 46 children previ-
ously transplanted in the Erasmus MC [17]. Possible differ-
ences between data from both populations were not formally 
tested.
2.2  Improved Dosing Algorithm
The cohort used to build an improved model consisted 
of a total of 95 children. Of these patients, 45 had been 
included in the development of the original model [17]. For 
the remaining patients, additional PK data were retrospec-
tively retrieved from the medical records. The 16 patients 
included in the clinical trial described above were added. 
The remaining 34 patients were transplanted in the Erasmus 
MC (n = 11) or in the Radboudumc (n = 23) between March 
2012 and October 2017. The Ethics Review Board of the 
Erasmus MC provided a waiver for the Medical Research 
Involving Human Subjects Act for this study (Medical Ethi-
cal Review Board number 2017-092). No extra laboratory 
analyses were performed.
2.2.1  Base Model and Covariate Model Development
Pharmacokinetic analysis was conducted by nonlinear 
mixed-effects modeling using NONMEM version 7.2 
(FOCE + I; ICON Development Solutions, Ellicott City, 
MD, USA) and PsN version 4.6.0. Pirana software was used 
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as an interface between NONMEM, R (version 3.2.2) and 
Xpose (version 4). Base model and covariate model devel-
opment was conducted as described previously [17]. The 
following demographic, clinical, and genetic characteris-
tics were evaluated as potential covariates: weight, height, 
sex, age, ethnicity, co-medication (glucocorticoids and 
calcium channel blockers), glucocorticoid dose, CYP3A4 
and CYP3A5 genotype, primary kidney disease, number of 
transplantations, renal replacement therapy prior to trans-
plantation (pre-emptive, peritoneal dialysis, or hemodialy-
sis), donor status (living or deceased), human leukocyte anti-
gen mismatches, time post-transplant, hematocrit, creatinine, 
estimated glomerular filtration rate (Schwartz formula [28]), 
aspartate aminotransferase, albumin, C-reactive protein, and 
total protein.
2.2.2  Model Evaluation
The final model was internally validated with a VPC with 
500 simulated datasets and a normalized prediction distri-
bution error analysis with 1000 simulations as described 
previously [17]. The VPC was stratified for the included 
covariates. To evaluate the effect of the significant covari-
ates, simulations were performed using the final model with 
varying parameters for the covariate. All other parameters 
were fixed to the mean.
2.2.3  Starting Dose Algorithm
To be able to predict the required tacrolimus starting dose, 
the final model was used to develop a starting dose algo-
rithm. Each significant covariate in the final model was 
evaluated if it was clinically relevant, feasible to use, and 
if it significantly influenced the starting dose of tacrolimus. 
The starting dose model was validated using the techniques 
mentioned above.
3  Results
3.1  Prospective Trial
The study was conducted between 19 November 2017 (first 
patient, first visit) and 19 February 2019 (last patient, last 
visit). A total of 19 patients was screened for participation in 
the trial of which 17 were eligible (Fig. 1). Sixteen patients 
gave written informed consent and were subsequently 
included (n = 13 in the Erasmus MC and n = 3 in Radbou-
dumc). Patient characteristics are shown in Table 1. Of these 
patients, 15 completed the 10-day follow-up. One patient 
was accidently administered tacrolimus extended release 
(Advagraf; Astellas Pharma) on day 5 and discontinued the 
study.
The CYP3A5 allele frequencies are shown in Table 1. The 
observed CYP3A5 genotype distribution was in accordance 
with the Hardy–Weinberg equilibrium (χ2 = 1.34; p = 0.25).
3.1.1  Endpoints and Discontinuation of the Study
At the pre-planned interim analysis (after the inclusion of 
n = 16 children), five children (31%) had a tacrolimus C0 
within the target range (10–15 ng/mL), 31% had a supra-
therapeutic C0, and 38% a subtherapeutic C0 on day 3 after 
transplantation (Table 2). This number was set before the 
study as a minimum to continue the study.
The algorithm predicted really high doses (i.e., 0.80 mg/
kg/day) in patients who were CYP3A5 expressers and 
received a kidney from a deceased donor (n = 3). Consider-
ing these high doses, in these patients, a tacrolimus C0 was 
measured already on day 1 or 2 following transplantation. 
These C0 were too high, and the tacrolimus dose was subse-
quently reduced before day 3 (the primary endpoint). Two 
children (12.5%) had a markedly sub-therapeutic tacrolimus 
C0 (< 5 ng/mL) on day 3, and three children (19%) had a 
markedly supra-therapeutic (> 20 ng/mL) tacrolimus C0 on 
day 3 after transplantation. After TDM was performed, three 
children (20%) had a tacrolimus C0 within the target range 
on day 7, compared with five children (36%) on day 10. The 
Fig. 1  Trial flowchart. All patients who underwent a kidney trans-
plantation and received at least one dose of tacrolimus according to 
the dosing algorithm were included in the intention-to-treat popula-
tion
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individual tacrolimus C0 during the follow-up is shown in 
Fig. 2. The tacrolimus C0 on days 3, 7, and 10 are shown in 
Fig. 3.
Although the a priori criteria for a successful study 
were met (31% of children on target at day 3 after trans-
plantation), we decided to discontinue the study prema-
turely and to improve the model using new data. The 
reasons for this were two fold. First, at the interim analy-
sis, it was discovered that the model performed poorly in 
CYP3A5 expressers receiving a kidney from a deceased 
donor, which constituted 25% of all children included in 
this prospective study. Second, there was considerable 
concern among clinicians regarding overdosing in patients 
who were CYP3A5 expressers and received a kidney from 
a deceased donor.
3.1.2  Safety
Overall, patient and graft survival was 100%. The incidence 
of biopsy-proven acute rejection during the follow-up was 
6.3% (n = 1). One child had antibody-mediated rejection on 
day 8 and was treated with methylprednisolone and immu-
noglobulins. At the time of biopsy, tacrolimus C0 was 3.9 ng/
mL. Just after the follow-up finished (day 13), one patient 
was diagnosed with acute cellular rejection Banff grade 2A 
and was treated with methylprednisolone. At the time of 
biopsy, tacrolimus C0 was 18.7 ng/mL. Both children fully 
recovered. The incidence of delayed graft function was 
6.25% (n = 1). Tacrolimus C0 on day 3 of this patient was 
21.4 ng/mL. During the 30 days after the follow-up period 
had finished, one patient reported a serious adverse event. 
This child developed post-transplant diabetes mellitus, and 
was switched to ciclosporin-based immunosuppressive ther-
apy, and fully recovered. At the time of diagnosis, tacrolimus 
C0 was relatively high (18 ng/mL).
3.2  Improved Dosing Algorithm
As the trial was ended prematurely, a new dosing algorithm 
was developed in an extended cohort. The model building 
cohort was expanded to a total of 95 children. Patient char-
acteristics are presented in Table 3. From these patients, a 
total of 1138 blood samples were collected and analyzed 
for tacrolimus concentrations (range 1.8–109.0 ng/mL). No 
samples were below the lower limit of quantification. One 
sample was above the upper limit of quantification and was 
discarded. A fifth of the samples was drawn within the first 
week following transplantation. For 90 patients, at least one 
PK profile at a median of 12.2 days (range 4.2–42.0 days) 
post-transplantation was available. The CYP3A4 and 
CYP3A5 allele frequencies are depicted in Table 3. There 
was no deviation from the Hardy–Weinberg equilibrium.
3.2.1  Pharmacokinetic Model Development
The data were best described with a two-compartment 
model. Including inter-individual variability on clearance 
(CL/F), volume of distribution of the central compartment, 
volume of distribution of the peripheral compartment, and 
the absorption rate constant significantly improved the 
Table 1  Patient characteristics
CAKUT congenital anomalies of the kidney and the urinary tract, 
CYP cytochrome P450, HLA human leukocyte antigen, RRT renal 
replacement therapy
a Presented as median and range for continuous variables
Clinical trial 
patients (n = 16)
Sex, n (%)
 Male 12 (75.0)
Age (years)a 15.0 (4.6–16.8)
Ethnicity, n (%)
 Caucasian 11 (68.8)
 Asian 0 (0)
 African descent 2 (12.5)
 Other 3 (18.9)
Bodyweight (kg)a 50.3 (15.7–80.4)
Height (cm)a 161 (101–179)
Genotype, n (%)
 CYP3A5
  *1/*1 1 (6.3)
  *1/*3 3 (18.9)
  *3/*3 12 (75.0)
 CYP3A4
  *1/*1 13 (81.3)
  *1/*1G 2 (12.5)
  *1G/*1G 1 (6.3)
Primary diagnosis, n (%)
 CAKUT 7 (43.8)
 Glomerular kidney disease 1 (6.3)
 Cystic kidney disease/nephronophthisis 3 (18.9)
 Other/unknown 5 (31.3)
RRT prior to kidney transplantation, n (%)
 Hemodialysis 5 (31.3)
 Peritoneal dialysis 3 (18.9)
 Pre-emptive 8 (50.0)
Donor type, n (%)
 Living 11 (68.8)
 Deceased 5 (31.3)
Number of HLA mismatches, n (%)
 0 2 (12.5)
 1 1 (6.3)
 2 3 (18.9)
 3 7 (43.8)
 4 3 (18.9)
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model fit. Allometric scaling with an estimated exponent 
on CL/F and fixed exponent on volume of distribution of 
the central compartment (1) and volume of distribution of 
the peripheral compartment (1) significantly improved the 
model (p < 0.001). The objective function value decreased 
further after adding inter-occasion variability on CL/F. 
The residual error was described with a combined additive 
and proportional error model for the immunoassay meas-
ured concentrations, and a separate additive and propor-
tional error model for the liquid chromatography–tandem 
Table 2  Clinical trial results
C0 pre-dose concentration, CYP cytochrome P450, DD deceased donor, LD living donor, NA not available, 
Tac tacrolimus
a Patients had a toxic tacrolimus C0 on days 1–2 following transplantation. The tacrolimus dose was subse-
quently reduced
b Patient had a concentration of 11 ng/mL after just one dose of tacrolimus. The tacrolimus dose was subse-
quently reduced
c Patient discontinued the study after accidental administration of Advagraf
Body-
weight 
(kg)
CYP3A5 Donor Day 3 Day 7 Day 10
Tac dose 
(mg/kg/day)
Tac C0 Tac dose 
(mg/kg/day)
Tac C0 Tac dose 
(mg/kg/day)
Tac C0
65 *3/*3 LD 0.31 11.3 0.31 17.8 0.25 14.9
80.4 *1/*3 DD 0.80 21.4a 0.22 35.0 0.22 15.7
48.2 *1/*1 DD 0.79 17.9a 0.29 15.3 0.37 4.6
51.3 *3/*3 DD 0.39 9.8 0.39 16.9 0.31 13.3
15.7 *3/*3 LD 0.38 7.4 0.51 12.0 0.51 9.7
70.1 *3/*3 LD 0.29 4.2 0.43 16.0 0.37 20.8
62.2 *1/*3 DD 0.64 11b 0.48 18.6 0.42 17.7
57.7 *3/*3 LD 0.29 11.9 0.33 22.2 0.26 13.7
29.9 *1/*3 LD 0.54 4.1 0.67 8.5 0.67 10.6
26.3 *3/*3 DD 0.46 7.2 0.61 14.6 0.53 14.4
39.3 *3/*3 LD 0.31 5.3 0.31 23.5 0.15 18.1
49.3 *3/*3 LD 0.28 24 0.20 17.4 0.12 16.7
41.5 *3/*3 LD 0.31 10.9 NAc NA NA NA
63.6 *3/*3 LD 0.31 10.3 0.31 11.7 0.19 8.0
59.3 *3/*3 LD 0.30 10.8 0.24 21.3 0.17 22.3
19.3 *3/*3 LD 0.36 21.3 0.26 21.3 0.21 NA
Fig. 2  Individual tacrolimus pre-dose concentrations (C0) in the 
10 days following kidney transplantation
Fig. 3  Boxplot depicting the tacrolimus pre-dose concentrations (C0) 
on days 3, 7, and 10 following transplantation. In this figure, the three 
patients who had a dose reduction before day 3 are excluded
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mass spectrometry measured concentrations. Parameter 
estimates of the base model, final model, and starting dose 
model are presented in Table 4.
After graphical analysis, the univariate analysis resulted in 
five significant covariates correlated with CL/F: hematocrit, 
CYP3A5, African descent, serum creatinine during follow-
up, and estimated glomerular filtration rate. After forward 
inclusion-backward elimination (stepwise covariate modeling 
method [29]), CYP3A5, hematocrit, and serum creatinine 
remained in the final model. The final model for estimation 
of tacrolimus CL/F in the first 6 weeks after transplantation 
is shown in Eq. (2):
The final model was used to develop a model to predict the 
starting dose of tacrolimus. As time after transplantation was 
not a significant covariate, the same database was used to cre-
ate the starting dose model. The last measured hematocrit and 
CL∕F = 36.6 ∗
(
weight
70
)0.62
∗ [(1.0, ifCYP3A5 ∗ 3∕ ∗ 3)
or (1.4, ifCYP3A5 ∗ 1∕ ∗ 3 orCYP3A5 ∗ 1∕ ∗ 1)]
∗
(
Hematocrit
0.29
)−0.6
∗
(
Creatinine
84
)−0.1
.
Table 3  Patient characteristics improved pharmacokinetic model
Model building 
cohort (n = 95)
Recipient sex, n (%)
 Male 58 (61)
Age of recipient (years) 11.4 (1.6–17.9)
Ethnicity, n (%)
 Caucasian
 Asian
 African descent
 Other
71 (74)
2 (2)
9 (9)
13 (14)
Bodyweight (kg)a 32.0 (10.4–87.5)
Height (cm)a 138 (73–188)
Laboratory measurements
 Hematocrit (L/L) 0.29 (0.16–0.52)
 Creatinine (µmol/L) 84 (12–1454)
 eGFR (mL/min) [28] 63 (2.9–274)
 ASAT (U/L) 29 (7–217)
 Albumin (g/L) 34 (11–52)
 CRP (mg/L) 6.4 (0.3–268)
 Total protein (g/L) 61 (34–80)
CYP3A4, n (%)
 *1/*1 34 (36)
 *1/*1G 8 (8)
 *1G/*1G 3 (3)
 *22 2 (2)
 Unknown 48 (51)
CYP3A5, n (%)
 *1/*1 3 (3)
 *1/*3 11 (12)
 *3/*3 52 (55)
 *3/*7 2 (2)
 Unknown 27 (28)
Primary diagnosis, n (%)
 CAKUT 46 (48)
 Glomerular kidney disease 22 (23)
 Cystic kidney disease/nephronophthisis 12 (13)
 Other/unknown 15 (16)
Number of kidney transplantations, n (%)
 First 90 (95)
 Second 5 (5)
RRT prior to kidney transplantation, n (%)
 Hemodialysis 28 (29)
 Peritoneal dialysis 23 (24)
 Pre-emptive 44 (46)
Donor type, n (%)
 Living 74 (78)
 Deceased 21 (22)
Route of administration, n (%)
 Suspension 24 (25)
 Capsule 89 (94)
Table 3  (continued)
Model building 
cohort (n = 95)
Co-medication, n (%)
 Calcium channel blockers
  Amlodipine 51 (54)
  Nifedipine 23 (24)
 Antibiotics
  Erythromycin 1 (1)
 Antimycotics
  Fluconazole 2 (2)
  Voriconazole 1 (1)
Distribution of tacrolimus samples
 Total samples 1338
 0–7 days post-transplantation 286 (21)
 8–14 days post-transplantation 515 (38)
 15–21 days post-transplantation 218 (16)
 22–42 days post-transplantation 319 (24)
Tacrolimus analysis
 Immunoassay 64 (4.8)
 LC–MS/MS 1274 (95.2)
ASAT aspartate aminotransferase, C0 pre-dose concentration, CAKUT 
congenital anomalies of the kidney and the urinary tract, CYP 
cytochrome P450, eGFR estimated glomerular filtration rate, LC–MS/
MS liquid chromatography–tandem mass spectrometry, RRT renal 
replacement therapy
a Presented as median and range for continuous variables
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serum creatinine before transplantation did not significantly 
influence the CL/F, and were not included in the starting dose 
model. Equation 3 describes the starting dose model:
To calculate the required dose, the PK formula of 
dose = CL/F * AUC can be used. A C0 of 10 ng/mL cor-
responded with an AUC 0–12h of 185 ng h/mL, 12.5 ng/mL 
with 220 ng h/mL, and 15 ng/mL with 254 ng h/mL. For a 
target of 12.5 ng/mL, this leads to Eq. (4) for the starting 
daily dose based on a twice-daily prescription (improved 
dosing algorithm):
CL∕F = 34.5 ∗
(
weight
70
)0.56
∗ [(1.0, ifCYP3A5 ∗ 3∕ ∗ 3)
or (1.46, ifCYP3A5 ∗ 1∕ ∗ 3 orCYP3A5 ∗ 1∕ ∗ 1)].
Dose (mg/day) = 220 ∗ 34.5 ∗
(
weight
70
)0.56
∗ [(1.0, ifCYP3A5 ∗ 3∕ ∗ 3)
or (1.46, ifCYP3A5 ∗ 1∕ ∗ 3
orCYP3A5 ∗ 1∕ ∗ 1)]∕1000.
An example of calculated doses according to Eq. (4) is 
given in Table S3 of the ESM.
3.2.2  Evaluation of the Final Model and Starting Dose 
Model
All estimates were within the limits, except for shrinkage 
on V3, which was 22%. Goodness-of-fit plots of the final 
model and starting dose model showed both the individual 
and population predictions were evenly distributed around 
the line of unity (Fig. 4). The median and variability of the 
C0 fell within the corresponding simulations as shown in the 
prediction-corrected VPCs (Fig. S1 of the ESM). Normal-
ized prediction distribution errors were acceptably deviated 
from a normal distribution and values were mostly between 
− 2 and 2, showing the adequate predictive ability of the 
model. A shark plot showed 68% of patients had a decrease 
in objective function value with the final model compared 
with the base model.
Table 4  Parameter estimates of 
the base model, final model, and 
bootstrap analysis
CL clearance, CYP cytochrome P450, F bioavailability, IIV inter-individual variability, IOV inter-occasion 
variability, ka absorption rate constant, LC–MS/MS liquid chromatography–tandem mass spectrometry, Q 
inter-compartmental clearance, RSE residual standard error, tlag lag time, V1 volume of distribution of the 
central compartment, V2 volume of distribution of the peripheral compartment
Parameter Base model (RSE %) 
[shrinkage]
Final model (RSE %) 
[shrinkage]
Starting dose model 
(RSE %) [shrinkage]
tlag (h) FIX 0.41 0.41 0.41
ka (L/h) 2.1 (19) 1.7 (11) 1.85 (24)
CL/F (L/h/70 kg) 37.0 (6) 36.6 (12) 34.5 (6)
V1/F (L/70 kg) 560 (12) 496 (22) 540 (12)
Q/F (L/h) 27.4 (16) 31.7 (19) 28.5 (12)
V2/F (L/70 kg) 1600 (13) 1270 (13) 1660 (17)
Allometric scaling on CL 0.57 (10) 0.62 (20) 0.56 (9)
Covariate effect on CL
 CYP3A5*1/*1 or *1/*3 – 1.4 1.5
 Hematocrit (L/L) – − 0.60 –
 Creatinine (µmol/L) – − 0.1 –
IIV (%)
 CL/F
 V1/F
 V2/F
 ka
47.2 (8) [4]
89.0 (12) [11]
92.1 (15) [20]
172 (10) [23]
42.1 (10) [5]
99.6 (12) [10]
85.2 (15) [22]
183 (11) [20]
42.3 (11) [3]
93.0 (12) [8]
89.3 (15) [19]
178 (10) [22]
IOV (%)
 CL/F 20.7 (9) 20.1 (20) 20.1 (10)
Residual variability
 Additional
  Immunoassay
  LC–MS/MS
0.77
0.94
1.27
0.87
1.01
0.96
 Proportional
  Immunoassay
  LC–MS/MS
0.12
0.23
0.11
0.23
0.12
0.24
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3.2.3  Simulations
Based on the final model, CYP3A5 expressers had a 1.4-fold 
higher CL/F than the CYP3A5 non-expressers. A decrease 
in hematocrit levels from 0.35 to 0.25 L/L corresponded 
with an 18% higher tacrolimus CL/F. A decrease in serum 
creatinine concentration from 500 to 50 µmol/L was associ-
ated with a 21% increase in CL/F. The effect of CYP3A5, 
bodyweight, serum creatinine, and hematocrit are shown in 
Fig. S2 of the ESM. In total, these covariates explained 39% 
of the variability in CL/F.
4  Discussion
In this prospective trial, 31% (five out of 16) of the chil-
dren had a tacrolimus C0 within the target range on day 
3 following transplantation when prescribed a tacrolimus 
starting dose based on the original dosing algorithm. Two 
children (12.5%) had a markedly subtherapeutic tacrolimus 
C0 (< 5 ng/mL) on day 3, and 3 (19%) had a markedly 
supratherapeutic (> 20 ng/mL) tacrolimus C0. The origi-
nal algorithm performed worse than anticipated and was 
comparable to the weight-based prescription, and therefore 
the trial was ended prematurely.
Fig. 4  Goodness-of-fit plots of the final model. a Observed concen-
trations (OBS) DV plotted against predicted concentration (PRED). b 
DV plotted against individual predicted concentration (IPRED). c The 
correlation of conditional weighted residuals (CWRES) with the time 
after the tacrolimus dose. d The correlation of CWRES with PRED. 
The line represents the line of identity. DV dependent variable (meas-
ured concentration)
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Contrary to what we expected, only 31% of patients 
had a tacrolimus C0 within the target range. When the 
tacrolimus starting dose is only based on bodyweight in 
children, 30% is on target on day 3 [17]. For the model to 
be a meaningful addition to standard bodyweight-based 
dosing, our estimate was that at least 55% would have to 
be on target. Based on our results, it seems that basing the 
starting dose on the original dosing algorithm does not 
increase the percentage of patients on target and does not 
reduce the number of extreme high and low tacrolimus C0 
compared with standard bodyweight-based dosing.
There is compelling evidence that CYP3A5 expressers 
require a 1.5- to 2-fold higher tacrolimus dose than non-
expressers [15, 17–19, 30–36]. A randomized clinical trial 
of age- and genotype-guided tacrolimus dosing in children 
concluded that CYP3A5 genotype-guided dosing stratified 
by age resulted in earlier attainment of therapeutic tacroli-
mus concentrations and fewer out-of-range concentrations 
[37]. Clinical outcomes were not studied. Two large clinical 
trials in adults studied whether basing the tacrolimus dose 
on CYP3A5 would lead to more patients within the target 
C0 range. Both studies concluded that optimization of the 
initial tacrolimus dose using CYP3A5 genetic testing does 
not improve clinical outcomes when TDM is performed [38, 
39]. As the variability in CL is not solely based on CYP3A5, 
basing the starting dose on a dosing algorithm including 
clinical, genetic, and demographic factors seemed the sen-
sible next step.
On day 3 following transplantation, five patients were 
on target. As they were all CYP3A5 non-expressers who 
received a kidney from a living donor, they were all pre-
scribed a dosage of approximately 0.3 mg/kg/day. This is the 
same dose as the standard bodyweight-based dose according 
to the package leaflet [40]. These children would have been 
on target regardless if they participated in this trial.
Six children had a subtherapeutic tacrolimus C0 on day 
3. All of these children received a dose between 0.29 and 
0.54 mg/kg/day, which is equal to or higher than the standard 
bodyweight-based dose of 0.3 mg/kg. This suggests that if 
they had not participated in the trial and received a standard 
bodyweight-based dose, these children would also all have 
had a subtherapeutic tacrolimus exposure. Of these children, 
one was a CYP3A5 expresser and one received a kidney 
from a deceased donor. The doses were calculated correctly. 
It seems other factors not included in the original algorithm 
increased tacrolimus CL in these patients.
In three patients, the tacrolimus dose was reduced on 
days 1–2 following transplantation owing to a high tacroli-
mus C0. If these doses had not been reduced, these patients 
would have likely had toxic tacrolimus C0 on day 3. These 
patients all received a kidney from a deceased donor and 
were CYP3A5 expressers. It seems that the original dosing 
algorithm overestimates the CL of tacrolimus in this group, 
and therefore overestimates the required tacrolimus dose. To 
our knowledge, no other publication has found a relation-
ship between donor type and tacrolimus CL. As tacrolimus 
undergoes hepatic metabolism, a higher tacrolimus CL in 
kidneys from a deceased donor seems highly unlikely. All 
patients received the same immunosuppressive protocol, no 
patients experienced delayed graft function. Dialysis prior 
to transplantation and the number of human leukocyte anti-
gen mismatches were not significantly associated with the 
tacrolimus CL. The higher tacrolimus CL in kidneys from 
a deceased donor is probably caused by other unknown 
parameters that could not be tested as covariates and there-
fore cannot be corrected for. The cohort in which the model 
was developed [17] consisted of 46 children of whom only 
two were CYP3A5 expressers and received a kidney from a 
deceased donor. It seems that there was insufficient power in 
the cohort in which the model was developed to determine 
adequate tacrolimus exposure predictions in this specific 
subgroup.
After improving the original dosing algorithm, CYP3A5 
expressers required a 1.4-fold higher tacrolimus dose than 
CYP3A5 non-expressers in the improved dosing algorithm. 
This is in line with previous research mentioned above. 
As approximately 70–80% of tacrolimus is distributed in 
erythrocytes, low hematocrit reduces the whole-blood con-
centration of tacrolimus [41]. In this study, we concluded 
that patients with a higher hematocrit had a lower CL/F. 
Previous research substantiates these findings [17, 19, 31, 
35, 36, 42–45]. Hematocrit did not influence the starting 
dose and was therefore not included in the dosing algorithm. 
Patients with higher serum creatinine levels had a decreased 
CL/F. Tacrolimus undergoes hepatic elimination and almost 
no renal elimination, thus the explanation for this observa-
tion remains unclear. Some studies have reported a corre-
lation between creatinine and tacrolimus CL [31, 46, 47], 
whereas others found no such effect [48–50]. Four decades 
previously, Sheiner et al. concluded that forecasting a con-
centration based on covariates does not improve accuracy 
and precision as much as one previous concentration [51]. 
However, when predicting the optimal starting dose, no pre-
vious concentrations are available. In this first exploratory 
study, we chose to focus on the starting dose with a historic 
cohort. For a new study, it will be interesting to adjust the 
subsequent doses using the dosing algorithm in combination 
with the previous concentration rather than just TDM.
The main difference between the improved PK model and 
the original model used to determine the tacrolimus starting 
dose in this trial is that donor status was no longer a signifi-
cant covariate on CL. It remains unclear why a recipient of 
a kidney from a deceased donor would have a higher tacroli-
mus CL. The other difference between the two models is that 
allometric scaling was coded with an estimated exponent 
on CL and CYP3A5 expressers should receive a 1.46-fold 
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higher dose in the improved algorithm compared with 1.82 
in the original. Simulations of the improved model showed 
better description of the data compared with the previously 
published model, as shown in the VPC (Fig. S3 of the ESM). 
It will be interesting to see if the improved model is able to 
adequately predict the tacrolimus exposure when used in 
clinical practice. We are currently planning a new prospec-
tive clinical trial using this new and improved algorithm.
The main strength of this study is that this is the first 
attempt at predicting the optimal starting dose of tacroli-
mus in children in clinical practice with a dosing algorithm. 
Many PK models that have been published in the literature 
were developed retrospectively but were not tested in pro-
spective studies. This study has demonstrated that even 
though on paper the algorithm was validated extensively 
and performed well, in clinical practice, it was simply inad-
equate. As the old proverb says, the proof of the pudding is 
in the eating. A second strong point is that because of the 
chosen methodology, a limited sample size was sufficient 
to answer the research question. The final strength of this 
study is that an improved starting dose model was developed 
and designed for clinicians, making it easy to use the dosing 
algorithm in clinical practice.
The main limitation of this study is that in the PK model 
building cohort two different analytical techniques were 
used: immunoassay and liquid chromatography–tandem 
mass spectrometry. However, to solve this issue, this differ-
ence was built into the residual error model. We chose not 
to exclude the immunoassay concentrations as they were 
included in the original model. Furthermore, the relatively 
large proportion of Caucasian patients in our center is a limi-
tation as this may not reflect pediatric transplant populations 
worldwide.
5  Conclusions
In a prospective study, a validated tacrolimus dosing algo-
rithm was poorly predictive of the individual tacrolimus 
starting dose following renal transplantation in children. 
On day 3, a total of only 31% of patients was within the 
target tacrolimus pre-dose concentration range. The dosing 
algorithm was subsequently improved using data of children 
included in this trial and was able to adequately describe 
the tacrolimus pharmacokinetics the first 6 weeks follow-
ing kidney transplantation. The weight-normalized start-
ing dose of tacrolimus should be higher in patients with a 
lower bodyweight and in those who are CYP3A5 expressers. 
However, as the negative result of this trial demonstrates, a 
prospective study is needed to demonstrate the accuracy of 
this improved model.
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